ClinicalTrials.gg
RecruitingNCT06445231ECHOGERUpdated Oct 8, 2026

Echocardiography in Nursing Home

An interventional study of Implementation of echocardiography in nursing homes in Heart Diseases, Heart Failure and Heart Valve Diseases, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Heart Diseases with a site in France — 29 open to participants now, 37 under way, 5 of them phase 3. Heart Diseases · France.

Planned enrollment
21st of 79
1,050 · median 240
Started
2024
with 6 others
No phase
48 of 126
9 open now
Primary completion
2028-10
later than 25 of 36 live
Registered
112th of 126
by date

Among the 126 studies in Heart Diseases with a site in France, this one is the 21st largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2024, is one of 48 with no phase, reaches primary completion later than 25 of the 36 other live ones, and was the 112th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

29 of the 126 studies in Heart Diseases with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Heart Diseases with a site in France, or all of them as a file.
02

Study summary

The study seeks to explore the implementation characteristics (acceptability, appropriateness, feasibility, adoption, fidelity, penetration, implementation cost and sustainability) of systematic echocardiography in nursing homes and its impact on rates of heart failure flare-up and unscheduled hospitalization at 12 months among included nursing homes.

Read the detailed description

Open-label cluster randomized type 1 hybrid trial, with 2 parallel arms: nursing homes will be randomized in the interventional (echocardiography by sonographer) or non-interventional arms (usual care). In the interventional arm echocardiography will be proposed to all residents of the nursing home at baseline. Clinical management will be adapted to the result of echocardiography by the general practitioner, in accordance with the cardiologist. The main objective is to assess the impact at 12 months of the initial performance of a systematic simplified echocardiography on the rate of nursing home residents presenting with heart failure episode or cardiovascular pathology. The Primary endpoint is the number of nursing home residents presenting a heart failure episode or an unscheduled hospitalization for heart failure or other cardiovascular pathologies at 12 months.

Thirty nursing homes and 1050 residents will be included overall

03

Conditions studied

  • Heart Diseases
  • Heart Failure
  • Heart Valve Diseases

Keywords

  • Echocardiography
  • Nursing Home
  • Implementation
  • Heart Failure
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Nursing homes residents with a life-expectancy estimated > 1 year, and able to participate to the study, giving an oral consent

Exclusion criteria

Exclusion Criteria :

  • no accessible to echocardiography
  • closed unit (severe Alzheimer disease…)
  • recent contagious disease such Covid (\<15 days)
  • no consent to participate
  • no social security number
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,050 participants (estimated)

Study arms

  • Experimental
    Echocardiographic screening arm

    Participants from nursing homes allocated to echocardiographic screening group will benefit of one echocardiography at inclusion.

    Diagnostic Test: Implementation of echocardiography in nursing homes

  • No intervention
    Usual care

    Participants from nursing homes allocated to no-screening group. Participants will be followed for medical management and care as usual.

Interventions

  • Diagnostic testImplementation of echocardiography in nursing homes

    An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.

06

What researchers measure

Primary outcomes

  1. Count of resident presenting a heart failure decompensation

    Number of residents with heart failure flare (worsening of at least 1 NYHA class) or unplanned hospitalization for heart failure

    Time frame: 12 months

Secondary outcomes

  1. Presence of a clinically significative change in medical management and care in the month following ultrasound

    A binary outcome will be constructed, based on the following algorithm: clinically significative change set to "yes" if a change in ongoing drug prescription is observed, and/or a cardiologist visit is planned, and/or a geriatrist visit is planned, and/or an hospitalization for clinical work-up is set, and/or a resume of the ultrasound is sent to the GP. Otherwise (all components set to "absent"), this outcome will be set to "None".

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2028, 48 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 48 months is above that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jan 2028 → Oct 2028 and completion Jan 2030 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
Jun 6, 2024
StartActual
Oct 2, 2024
Primary completionEst.
Oct 2, 2028was Jan 2028
CompletionEst.
Oct 2, 2030was Jan 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2028→Oct 2, 2028
Oct 8, 2026
Study completion
Jan 1, 2030→Oct 2, 2030
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Jan 1, 2028→Oct 2, 2028
    Study completion Jan 1, 2030→Oct 2, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06445231
Collaborators
Directorate of Health Care Supply
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Oct 2, 2024
Primary completion
Oct 2, 2028 (estimated)
Completion
Oct 2, 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Thierry LE TOURNEAU, PU-PH
Contact
thierry.letourneau@chu-nantes.fr
33 2 40 16 54 98
Anne-Sophie BOUREAU, PH
Contact
annesophie.boureau@chu-nantes.fr
33 2 40 16 85 35
Thierry LE TOURNEAU, PU-PH
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion